MedTrace Logo

Pramipexole and the Risk of Serious Adverse Events

NCT07382960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2026-02-03

No results posted yet for this study

Summary

This is a population-based cohort study assessing whether initiation of a higher dose of pramipexole (0.25 or 0.375 mg/day), compared with a lower dose (0.125 mg/day), in older adults with advanced chronic kidney disease (CKD) (an estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m² but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 30-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits, or all-cause mortality.

Conditions

  • Older Adults (65 Years and Older)
  • Chronic Kidney Disease (CKD)

Interventions

DRUG

Pramipexole

The primary exposure of interest will be oral pramipexole at a 0.125 mg/day. For the primary comparison, this dose has been selected to reduce the potential influence of indication bias.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Amit Garg · London Health Sciences Centre Research Institute

Eligibility

Min Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-01
Primary Completion
2024-12-01
Completion
2024-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07382960 on ClinicalTrials.gov